Gastrointestinal enzymes

Gastrointestinal enzymes represent a broad and heterogeneous group of catalytic proteins secreted by the salivary glands, stomach, pancreas, and small intestine to facilitate the breakdown of complex dietary macronutrients into absorbable units [StatPearls, NBK537021]. This class includes essential hydrolases such as proteases (e.g., pepsin, trypsin) for protein digestion, lipases for lipid hydrolysis, and amylases and disaccharidases for carbohydrate processing [NIH, National Institute of Diabetes and Digestive and Kidney Diseases]. In clinical practice, these enzymes serve as critical therapeutic targets; they are administered as replacement therapy in conditions like exocrine pancreatic insufficiency (EPI) and cystic fibrosis to prevent malnutrition and steatorrhea [PubMed, 31631670]. Conversely, specific enzymes within this group are targeted for inhibition to manage metabolic diseases, such as alpha-glucosidase inhibitors for type 2 diabetes and gastric/pancreatic lipase inhibitors for obesity management [PubChem, CID 4440]. Because the term 'Gastrointestinal enzymes' encompasses many distinct proteins with different substrates and locations, it is often treated as a therapeutic category rather than a single molecular target.

Other names

Digestive enzymesGastrointestinal hydrolasesAlimentary enzymesPancreatic enzymesBrush border enzymes

Drugs targeting these enzymes typically function either via Enzyme Replacement Therapy (ERT), where exogenous enzymes substitute for deficient endogenous production [StatPearls, NBK534814], or through competitive inhibition, where drug molecules bind to the enzyme's active site to prevent the breakdown and absorption of specific nutrients like fats or sugars [PubMed, 29076654].